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Abstract: Background: The link between cardiometabolic and psychiatric illness has long been
attributed to human behaviour, however recent research highlights shared biological mechanisms.
The ASTN2 locus has been previously implicated in psychiatric and cardiometabolic traits, therefore
this study aimed to systematically investigate the genetic architecture of ASTN2 in relation to a
wide range of relevant traits. Methods: Baseline questionnaire, assessment and genetic data of
402111 unrelated white British ancestry individuals from the UK Biobank was analysed. Genetic
association analyses were conducted using PLINK 1.07, assuming an additive genetic model and
adjusting for age, sex, genotyping chip, and population structure. Conditional analyses and linkage
disequilibrium assessment were used to determine whether cardiometabolic and psychiatric signals
were independent. Results: Associations between genetic variants in the ASTN2 locus and blood
pressure, total and central obesity, neuroticism, anhedonia and mood instability were identified. All
analyses support the independence of the cardiometabolic traits from the psychiatric traits. In silico
analyses provide support for the central obesity signal acting through ASTN2, however most of the
other signals are likely acting through other genes in the locus. Conclusions: Our systematic analysis
demonstrates that ASTN2 has pleiotropic effects on cardiometabolic and psychiatric traits, rather
than contributing to shared pathology.
Keywords: ASTN2; cardiovascular disease; metabolic disease; psychiatric illness; anhedonia; mood
instability; neuroticism; BMI; central obesity; blood pressure
1. Introduction
Individuals with serious mental illnesses (SMI, such as schizophrenia, bipolar disorder,
and major depressive disorder) suffer from physical diseases at a higher frequency than
unaffected individuals and have excess mortality to reflect this—the life expectancy is
25 years shorter on average than the general population, largely attributable to cardiovas-
cular disease [1,2]. Non-genetic factors are commonly used to explain the co-existence
between mental and cardiometabolic health conditions, such as lifestyle factors, illness-
related factors, and treatment-related factors. For example, individuals with depressive
disorders are more likely to smoke and to be obese than non-depressed individuals [1,3].
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However, with an increasing understanding of genetics, new theories are emerging that
link SMI and physical health on a molecular level, and introduce the possibility of shared
genetic predisposition [4].
Through numerous genome-wide association studies (GWAS), the ASTN2 locus has
been identified as associated with both cardiometabolic and psychiatric traits. Psychiatric
associations with ASTN2 single nucleotide polymorphisms (SNPs) include those with
bipolar disorder (BPD) [5,6], major depressive disorder (MDD) [7–9], and response to
anti-psychotic treatment [10]. Cardiometabolic associations include blood pressure [11–13],
measures of obesity [13–16] and glucose homeostasis [17]. The ASTN2 gene encodes
astrotactin, a membrane protein [18] implicated in synaptic function [19]; thus, while a role
in psychiatric traits is logical, how the ASTN2 locus might influence cardiometabolic traits
is less clear.
We set out to systematically investigate in primary data whether genetic variation
in the ASTN2 locus could contribute to the shared genetic predisposition and potentially
shared pathology of cardiometabolic and psychiatric illness, using the UK Biobank dataset.
2. Materials and Methods
2.1. Cohort and Phenotyping
The UK Biobank study has been described in open-access publications [20–22]. Briefly,
~500,000 volunteers were recruited to the UK Biobank study between 2006–2010, from
22 centres around the UK. At baseline, all individuals underwent a physical examination
and completed extensive questionnaires on personal and family medical history and
lifestyle. Additional mental health questionnaires and imaging have been completed by
a subset of individuals in follow-up requests for data. At baseline, a blood sample was
collected and stored appropriately for DNA extraction (buffy coat fraction in EDTA tubes,
stored at −80◦C (https://www.ukbiobank.ac.uk/media/gnkeyh2q/study-rationale.pdf,
accessed on 28 July 2021) and for biomarker analysis. DNA extraction enabled genome-
wide genotyping of all individuals which was conducted using 2 genotyping platforms,
with a large proportion of overlapping SNPs [20]. Quality control and imputation of genetic
data was conducted centrally by UK Biobank, using standard protocols [20]. This study
was covered by the generic ethical approval for UK Biobank studies from the NHS National
Research Ethics Service (approval letter dated 29 June 2021, Ref 21/NW/0157). This project
was completed under UK Biobank applications 6553 (PI. RJS) and 7155 (PI. JPP).
Anthropometric measurements of height, weight, waist and hip circumferences were
used to calculate body mass index (BMI, reflective of total obesity) and waist:hip ratio
adjusted for BMI (WHRadjBMI, reflecting central adiposity, as per Shungin et al. [23]).
Systolic and diastolic blood pressure (SBP and DBP respectively) were measured twice,
and the average values were adjusted (as per Ehret et al. [24]: SBP + 15 mmHg and
DBP + 10 mmHg if an individual reported use of an anti-hypertensive medication) to
correct for anti-hypertensive medication effects. Type 2 diabetes was defined according
to Eastwood et al. [25] based on self-report or anti-diabetic medication. Ischemic heart
disease (ISH) and Stroke were defined by self-report (#6150, Heart attack/Angina and
Stroke, respectively). Venous thromboembolism was defined by self-report (for deep-vein
thrombosis and/or pulmonary embolism, #6152). The baseline questionnaire was used
to assess risk-taking behaviour (#2040, “Would you describe yourself as someone who
takes risks?”) and mood instability (#1920, “Does your mood often go up and down?”),
neuroticism (#20127), and anhedonia (#2060, “over the past two weeks, how often have you
had little interest or pleasure in doing things?”). For anhedonia, individuals responding
“not at all” were considered controls whilst individuals responding with “several days”,
“more than half the days” or “nearly every day” were considered cases. A follow-up
“thoughts and feelings” questionnaire (2016–2017) was used to assess lifetime MDD, BD
and generalised anxiety disorder (GAD) [26]. Individuals responding “don’t know” or
“prefer not to say” were excluded. Current smoking was defined by baseline self-report
(#20116) with never and former smokers being combined. In a subset of individuals, carotid
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intima media thickness (IMT) was measured by ultrasound as previously described [27].
Briefly, a single point in the carotid artery was measured at two projections and the mean
and maximum values were calculated.
2.2. Genetic Data
Genetic variation in the ASTN2 locus (defined as the ASTN2 gene +/−250 kb, UCSC (
https://genome-euro.ucsc.edu/cgi-bin/hgGateway?redirect=manual&source=genome.ucsc.
edu, accessed on 14 October 2020) build 37, chromosome 9: 118,935,000–120,428,000 (14 Oc-
tober 2020) was selected. Analyses were restricted to unrelated individuals of white British
ancestry and SNPs with minor allele frequencies (MAF) < 1% were excluded.
2.3. Statistical and Genetic Analyses
Genetic analyses were conducted using PLINK 1.07 [28], assuming an additive genetic
model. WHRadjBMI was analysed without covariates (as these are included in the construc-
tion of the phenotype). All other analyses were adjusted for age, sex, population structure,
(eight genetic principle components) and genotyping chip. Analyses of ISH and stroke also
included lipid-lowering and anti-hypertensive medication as covariates. Plink 1.07 [28],
was also used to calculate the number of independent loci (using–indep-pairwise and
default parameters), which was used for Bonferroni correction for multiple testing. This
gave a threshold of p value 5.45 × 10−5 for statistical significance. Results were visualised
using LocusZoom [29] and Haploview [30]. Descriptive statistics were calculated using
Stata 16.1 (StataCorp, College Station, TX, USA).
2.4. Conditional Analyses and Assessment of Linkage Disequilibrium
In order to assess (a) whether there were multiple signals for each trait and (b) the
independence signals between each trait, we carried out conditional analyses. Here we
reran all significant analyses including the lead SNP from each significant trait as a co-
variate. As a complimentary approach, we used Haploview [30] to visualise the linkage
disequilibrium (LD) between the lead SNPs.
2.5. In Silico Follow-Up Analyses
We used the GWAS catalogue (https://www.ebi.ac.uk/gwas/, accessed on 25 April 2021)
to search for traits that have previously been associated with the ASTN2 locus and compared
these to our own results. We also investigated the effects of lead SNPs on gene expression
levels using GTEx data (https://www.gtexportal.org/home/, accessed on 10 May 2021) and
the LDexpress tool (with CEU population and tissues of relevance to psychiatric and car-
diometabolic diseases selected (brain, nerve, adipose, artery, skeletal muscle, pancreas, liver
and pituitary). Lead SNPs and those with LD > 0.8 R2 and GTEx p < 1 × 10−5 were considered
(https://ldlink.nci.nih.gov/?tab=ldexpress, accessed on 14 October 2020). The most signifi-
cant SNPs for each gene and tissue were reported. In addition, we investigated the predicted
functional effects of all SNPS meeting the significance threshold for any trait using Ensembl
Variant Effect Predictor (VEP) (https://asia.ensembl.org/info/docs/tools/vep/index.html,
accessed on 10 May 2021).
3. Results
The characteristics of the cohort are presented in Table 1.
3.1. ASTN2 Genetic Variations in Cardiometabolic Traits
Significant associations (Table 2 and Figure 1A–D) were observed in the ASTN2 locus
for SBP (4 SNPs, lead SNP rs4837585-T, β (SE) −0.189 (0.044) p = 2.02 × 10−5), DBP (35 SNPs,
rs4837585-T, −0.119 (0.026) p = 3.56 × 10−6), BMI (89 SNPs, rs55654527-A, −0.063 (0.011)
p = 1.92 × 10−8) and WHRadjBMI (192 SNPs, rs13283416-G, −0.0008 (0.001) p = 4.52 × 10−9).
In conditional analyses, where the primary SNP from each analysis was included as a
covariate, no secondary signals were observed for SBP (Figure 2B), but secondary signals
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were evident for DBP (rs34432054-T, primary analyses values 0.174 (0.038), p = 4.97 × 10−6.
Figure 3) and BMI (rs415978-A, 0.052 (0.011), p = 1.75 × 10−6. Figure 4). Whilst two
SNPs remain significant when adjusting for the primary and secondary signals for DBP
(Figure 3C), these variants were not significant in the original analysis of DBP therefore are
not considered to be a tertiary signal. Further conditional analyses including primary and
secondary lead SNPs as covariates identified tertiary signals for BMI (rs10491574-T, 0.078
(0.017), p = 2.05 × 10−6, Figure 4C). No secondary signals were identified for WHRadjBMI
(Figure 5B).
Table 1. Descriptions of the UK Biobank participants included in this study.
Men Women All
N (% Male participants) 184,861 217,250 402,111 (46.0)
Age (years) 57.1 (8.1) 56.7 (7.9) 56.9 (8.0)
BMI (kg/m2) 27.8 (4.2) 27.0 (5.1) 27.4 (4.8)
WHRadjBMI 0.936 (0.065) 0.817 (0.070) 0.872 (0.09)
SBP (mmHg) 141 (17) 136 (19) 138 (17)
DBP (mmHg) 84 (10) 81 (10) 82 (10)
SBPadj (mmHg) 145 (19) 138 (21) 141 (21)
DBPadj (mmHg) 87 (11) 83 (11) 84 (11)
Hypertension 107,646 (60.9) 97,820 (47.3) 205,466 (53.6)
Anti-hypertensive medication 4328 (2.3) 2770 (1.3) 7098 (1.8)
Lipid-lowering medication 42,600 (25.9) 27,461 (15.6) 70,061 (20.6)
IMTmean * 0.706 (0.135) 0.658 (0.109) 0.681 (0.125)
IMTmax * 0.951 (0.216) 0.874 (0.185) 0.911 (0.204)
IMTmeanmax * 0.823 (0.159) 0.764 (0.131) 0.792 (0.148)
ISH 13,155 (9.8) 5199 (3.1) 18,354 (6.1)
Stroke 3665 (3.0) 2471 (1.5) 6138 (2.1)
Venous thromboembolism 4317 (3.2) 6112 (4.1) 10,429 (3.7)
Type 2 diabetes 11,149 (6.0) 6207 (2.9) 17,356 (4.3)
Current Smoking 21,780 (11.8) 18,769 (8.7) 40,549 (10.1)
Anhedonia 36,860 (19.9) 41,873 (19.3) 78,733 (19.6)
Mood instability 77,034 (41.7) 100,647 (46.3) 177,681 (44.2)
Neuroticism scores 3.58 (3.19) 4.57 (3.24) 4.11 (3.26)
Risk-taking 60,289 (33.6) 37,966 (18.1) 98,255 (25.3)
GAD ** 3063 (7.2) 6018 (12.8) 9081 (10.1)
BD ** 873 (0.5) 997 (0.5) 1870 (0.5)
MDD ** 9661 (5.5) 21,163 (10.3) 30,824 (8.1)
Where continuous variables are presented as mean (standard deviation) and binary variables as N (%). IMT, carotid
intima-media thickness; ISH, ischemic heart disease; GAD, generalised anxiety disorder; MDD, major depressive
disorder; BD, bipolar disorder. * only available for 22,179 individuals.** only available for 128,751 individuals.
3.2. ASTN2 Genetic Variations in Psychological and Psychiatric Traits
Significant associations (Table 2 and Figure 1E–G) were also identified for neuroticism
(rs579017-T, 0.084 (0.017) p = 3.58 × 10−7), anhedonia (2 SNPs, rs144850429-T, OR (95%
confidence intervals) 1.12 (1.06–1.18) p = 3.52 × 10−5) and mood instability (38 SNPs,
rs13284474-T, 0.98 (0.97–0.99) p = 7.42 × 10−7). Of note, rs13284474 is both the lead SNP for
primary mood instability and tertiary BMI signals.
Conditional analyses identified secondary (but not tertiary) signals for neuroticism
(rs2296672-T, 0.036 (0.008) p = 1.28 × 10−5, Figure 6B,C) and anhedonia (rs35979833-AG,
1.03 (1.02–1.05), p = 4.03 × 10−5, Figure 7B,C), whilst secondary and tertiary signals
were identified for mood instability (rs79825568-A, 0.98 (0.97–0.99), p = 1.46 × 10−5 and
rs4836751-A, 1.03 (1.02–1.05), p = 2.52 × 10−5, respectively, Figure 8B,C).
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Table 2. Results of main analyses.
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Figure 1. Regional plots for associations between ASTN2 and (A) SBP, (B) DBP, (C) BMI and (D) WHRadjBMI, (E) neuroticism, (F) anhedonia and (G) mood instability. Significance was 
set at p-value < 5.45 × 10−5 or −log10 > 4.26 (Horizontal yellow line). LD (r2) with the lead SNP are indicated by colour. Grey indicates that there is no LD information available. 
Figure 1. Regional plots for associations between ASTN2 and (A) SBP, (B) DBP, (C) BMI and (D) WHRadjBMI, (E) neuroticism, (F) anhedonia and (G) mood instability. Significance was set
at p-value < 5.45 × 10−5 or −log10 > 4.26 (Horizontal yellow line). LD (r2) with the lead SNP are indicated by colour. Grey indicates that there is no LD information available.
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SNP are indicated by colour. Grey indicates that there is no LD information available.
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3.3. Cross-Trait Observations
The SNPs significantly associated with blood pressure traits or BMI demonstrated consis-
tent effect directions on the other cardiovascular/metabolic traits (Supplementary Table S1),
so the SBP-increasing allele had a positive effect on DBP and a positive effect on BMI. Because
of the way WHRadjBMI is calculated, as an absolute value it is hard to interpret, so it has
been omitted from these comparisons.
SNPs significantly associated with anhedonia, neuroticism or mood instability demon-
strated consistent effect directions on the other psychological traits (Supplementary Table S1),
so the allele associated with increased neuroticism was also associated with increased risk of
anhedonia and increased risk of mood instability.
3.4. Genetic Architecture of the ASTN2 Locus
Considering the LD between the lead SNPs for all trait signals (Figure 9), it appears
that they are largely independent which is consistent with the results of the conditional
analyses, with only moderate LD between any two SNPs.
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Conditional analyses were also used to assess whether the cardiometabolic signals
were independent or overlapped with those for mental health traits. Conditional anal-
yses demonstrated that the lead SNP for SBP remained significant after adjustment for
any other primary SNPs (Figure 2C–G), suggesting that the SBP SNP is independent of
all other signals. For DBP, adjustment for the other lead signals reduced but did not
remove associations of either the primary or secondary signals (Figure 3D–H). For BMI,
the primary, secondary and tertiary signals remained significant after adjustment for pri-
mary SNPs for blood pressure, WHRadjBMI and neuroticism (Figure 4D–F respectively),
however adjusting for the anhedonia primary SNP rendered the primary and secondary
signals non-significant (Figure 4G), whilst adjusting for the mood instability primary SNP
rendered the tertiary signal non-significant (Figure 4H). Therefore, BMI signals are not
completely independent from those for anhedonia and mood instability. When considering
WHRadjBMI, adjustment for the primary SBP/DBP SNP reduced but did not remove the
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association (Figure 5C), whereas there was no effect of adjustment for the other primary
signals (Figure 5D–G).
Adjusting neuroticism for the primary signals for SBP/DBP, BMI, WHRadjBMI or an-
hedonia had no impact on the associations (Figure 6D–G), whilst adjustment for the primary
mood instability signal rendered the secondary association non-significant (Figure 6H).
Adjusting the anhedonia analyses for the physical traits or neuroticism had no impact on
the associations (Figure 7D–H), whilst adjusting for the mood instability primary signal
rendered the anhedonia signals null (Figure 7H). The primary and secondary signals for
mood instability were uninfluenced by adjusting for the primary SNPs for other traits
(Figure 8D–H), however the tertiary mood instability signal was reduced by adjustment
for the primary BMI signal (Figure 8D).
3.5. Comparison with Previously Published Associations
Robustly reported associations with the ASTN2 locus are presented in Table 3. Of the
lead (primary, secondary or tertiary) SNPs, the lead SNP for WHRadjBMI (rs13283416)
has previously been robustly implicated in osteoarthritis [31] and estimated glomerular
filtration rate [32,33] whilst the lead SNP for neuroticism (rs579017) has previously been
reported for this trait in two studies [34,35]. The current and previous reports of rs579017-T
being associated with increased neuroticism are consistent. The allele associated with “poor
metabolic health” (increased SBP, DBP, BMI, rs13283416-G) was associated with increased
risk of osteoarthritis, which could be expected, however the positive relationship with
estimated glomerular filtration rate is unexpected. The association of rs13283416 with
multiple components of metabolic syndrome (clustering of increased blood pressures and
obesity with dyslipidaemia and diabetes (https://www.nhs.uk/conditions/metabolic-
syndrome/, accessed on 28 July 2021) is noteworthy: because of the growing evidence
of firstly, a bi-directional relationship between the brain and metabolic systems [36] and
secondly, the overlap in genetic regulation of eating disorders such as anorexia nervosa and
insulin signalling [37] (widely considered to be the underlying process linking metabolic
syndrome components).
SNPs which have previously been associated with either psychological or cardiometabolic
traits are presented in Table 3. Of note is the association between rs1861881-G and DBP, which
appear discordant between Evangelou et al. [11,12] and our results, however closer inspection
of the published results is consistent with our results (suggesting that there is an error with
the GWAS catalogue excerpt). Unfortunately, the reasons for the discrepancy between our
results for rs17292540 and those reported by Pulit et al. [15] are hard to clarify, as this SNP
was not available in that paper’s Supplementary Data.
With psychiatric traits, ASTN2 has been associated with a range of conditions—bipolar,
depression, autism, ADHD and schizophrenia [6–9]. Our findings are largely consistent
with these previous findings (Table 3), in that alleles associated with increased risk of
MDD [7,9], BD [5] and ADHD [38] are associated (non-significantly) with increased neu-
roticism, mood instability and anhedonia (Table 3). ASTN2 has also been associated with
migraines and chronic pain- an area known to correlate strongly with mental health [39,40].
Our results are consistent with these, with alleles increasing the risk of chronic pain or
migraines being associated with increased neuroticism and mood instability (Table 3).
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Table 3. Reported associations between the ASTN2 locus and psychological or cardiometabolic traits.
Published UK Biobank









23793025 Migraine b rs17303101 A 0.28 1.07 A G 0.291 −0.01 0.03 0.00 −0.0003 0.01 1.00 1.00
31676860 Brain regionvolumes b rs10983184 C T 0.359 −0.07 −0.04 0.01 0.0004 0.00 1.00 1.00
31676860 Brain regionvolumes b rs1040851
C A 0.424 −0.06 −0.01 0.00 0.0001 0.02 1.01 1.01





b rs7873551 C 42.42 C T 0.231 0.00 0.05 −0.01 0.0000 0.00 1.00 1.00
31676860 Brain regionvolumes b
rs7030607
A G 0.359 0.02 0.01 −0.01 0.0004 −0.02 0.99 1.00
31676860 Brain regionvolumes b A G 0.359 0.02 0.01 −0.01 0.0004 −0.02 0.99 1.00
27182965 Migraine b 1.05 A G 0.359 0.02 0.01 −0.01 0.0004 −0.02 0.99 1.00







A 3.80 A G 0.365 −0.04 0.01 −0.01 0.0000 0.02 1.01 1.00
22683712 Migraine c A 0.38 1.16 A G 0.365 −0.04 0.01 −0.01 0.0000 0.02 1.01 1.00
27322543 Migraine b A 0.36 1.05 A G 0.365 −0.04 0.01 −0.01 0.0000 0.02 1.01 1.00
23793025 Migraine–clinic-based b A 0.38 1.16 A G 0.365 −0.04 0.01 −0.01 0.0000 0.02 1.01 1.00
23793025 Migrainewithout aura b A 0.38 1.12 A G 0.365 −0.04 0.01 −0.01 0.0000 0.02 1.01 1.00
27322543 Migrainewithout aura b A 0.35 1.14 A G 0.365 −0.04 0.01 −0.01 0.0000 0.02 1.01 1.00
31194737 Multisitechronic pain b A 0.37 0.01 A G 0.365 −0.04 0.01 −0.01 0.0000 0.02 1.01 1.00
31676860 Brain regionvolumes b rs34979631
T C 0.225 0.01 0.06 −0.01 0.0000 0.01 1.01 1.00
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Published UK Biobank









31676860 Brain regionvolumes b T C 0.225 0.01 0.06 −0.01 0.0000 0.01 1.01 1.00
31676860 Brain regionvolumes b rs4837565
A G 0.139 0.14 0.10 0.01 0.0003 0.00 1.01 1.00
31676860 Brain regionvolumes b A G 0.139 0.14 0.10 0.01 0.0003 0.00 1.01 1.00
31676860 Brain regionvolumes b rs11792948
A G 0.359 0.05 0.05 0.00 0.0001 0.01 1.01 1.00
31676860 Brain regionvolumes b A G 0.359 0.05 0.05 0.00 0.0001 0.01 1.01 1.00
31676860 Brain regionvolumes b rs4837580 T C 0.39 −0.05 −0.03 −0.01 0.0005 0.00 1.00 1.01












b G 0.50 0.23 G T 0.426 0.11 0.07 0.00 −0.0008 0.00 0.99 0.99
30374069 Osteoarthritis(hip) b G 1.10 G T 0.426 0.11 0.07 0.00 −0.0008 0.00 0.99 0.99
30224653 Diastolic bloodpressure b rs1861881












a rs10983238 G C 0.233 0.02 0.00 0.01 −0.0008 −0.01 0.99 0.99
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rs12340737 A C 0.332 −0.12 −0.08 −0.01 0.0003 0.00 1.00 1.01





b rs811458 T C 0.317 0.01 0.02 0.01 −0.0007 0.00 1.00 0.99























b rs4836899 T 0.52 1.12 C T 0.461 0.10 0.05 −0.02 0.0001 −0.01 0.99 1.00
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Published UK Biobank













a rs10116120 T G 0.241 0.10 0.11 −0.03 −0.0002 −0.02 0.98 0.99







b rs10759881 A 1.03 C A 0.277 0.06 0.06 −0.03 −0.0002 −0.02 0.98 0.99











a rs4838255 0.14 T A 0.179 0.02 0.03 −0.02 0.0001 0.01 0.99 1.00
31043756 Bipolar Idisorder b rs7858026 T 0.48 1.08 T A 0.488 −0.04 −0.04 −0.02 −0.0001 0.00 1.00 1.00





a rs189233549 G 0.01 3.91
29500382 Neuroticism b
rs579017
T 0.06 5.65 T C 0.06 0.00 0.02 0.05 −0.0002 0.08 1.03 1.01
29942085 Neuroticism b T 5.47 T C 0.06 0.00 0.02 0.05 −0.0002 0.08 1.03 1.01
Where: RA, risk allele; RAF, risk allele frequency; a, samples size < 1000; b, sample size > 10,000; c, replication analysis conducted; bold indicates significant at p < 5.45 × 10−5 in UK biobank.
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In addition to GWAS, ASTN2 has been implicated in SCZ through candidate gene
studies, but this is largely through a very rare variant, and has shown variable results
in follow-up studies so does not offer much support to the role of ASTN2 in common
conditions [40]. Nevertheless, combining the results of all previous studies, there is a strong
suggestion of the significance of ASTN2 in psychiatric health, supporting the need for
further studies specifically focused on the ASTN2 locus.
With regards to cardiometabolic health, previous literature again demonstrates several
associations between ASTN2 and the cardiometabolic risk factors mentioned previously.
The reported association with increased risk of T2D (rs1885234-G) [41] is consistent with
increased SBP (but not DBP) and WHRadjBMI observed here. Notably, a pathway analysis
demonstrated a connection between ASTN2 and plasma triglycerides which further sug-
gested the possible influence on neuronal pathways and insulin sensitivity, contributing
to obesity and T2D [42]. The novelty of the mechanism proposed and the relatively small
sample size of that study (N = 1000 individuals) means that verification of this association
is warranted.
3.6. Functional Assessment of ASTN2 Genetic Variants
LD Express and GTEX were used to identify SNPs with genotype-specific effects on
gene expression levels in relevant tissues. Results of protein-encoding genes are presented
in Table 4 (of note, no data was available for rs415978, rs2296672, rs35979833, rs13284474
and rs79825568). While there were several SNPs with genotype-specific effects on RP11-
500B12.1 in brain, nerve, pancreas and pituitary tissues, the significance is unclear, as this
hypothetical gene has no known function.
There is limited evidence for ASTN2 being the gene through which the lead SNPs
(or their LD proxies) have their effects: a proxy (r2 = 0.92) for the WHRdajBMI lead SNP
demonstrated reduced levels of ASTN2 expression with the WHRadjBMI-decreasing allele
in subcutaneous adipose tissue (Figure 10A), and a proxy (r2 = 1.0) for the anhedonia lead
SNP demonstrated reduced levels of ASTN2 in nerve tissue for the allele that increased
risk of anhedonia (Figure 10B). Relaxing the gene expression p value to <0.05 meant an
additional 3 proxies for the WHRadjBMI lead SNP were significantly associated with
ASTN2 levels, suggesting that this result is not due to different sample sizes and power for
the different tissues.
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Table 4. Genotype-specific expression patterns in relevant tissues.
Signal Query Direction EA EAF RSID R2 Gene Tissue Non-Effect Allele NEA EA Size p-Value
SBP/DBP-1 rs4837585 - T 0.46
rs7863794 0.92 PAPPA Muscle - Skeletal A = 0.535 G = 0.465 0.164925 8.09 × 10−6
rs811689 0.92 PAPPA Muscle - Skeletal C = 0.535 T = 0.465 0.161858 9.87 × 10−6
rs7857286 0.92 TRIM32 Adipose - Visceral (Omentum) C = 0.535 T = 0.465 0.177953 8.28 × 10−7
rs1661294 0.90 TRIM32 Adipose - Visceral (Omentum) G = 0.54 A = 0.46 0.175288 8.46 × 10−7
rs10817910 0.92 TRIM32 Adipose - Visceral (Omentum) C = 0.535 A = 0.465 0.176971 1.04 × 10−6
rs1885242 0.92 TRIM32 Adipose - Visceral (Omentum) G = 0.535 A = 0.465 0.176971 1.04 × 10−6
rs9775101 0.92 TRIM32 Adipose - Visceral (Omentum) C = 0.535 T = 0.465 0.176971 1.04 × 10−6
DBP-2 rs34432054 T + 0.13
rs34789583 1.00 TLR4 Whole Blood G = 0.874 A = 0.126 −0.19938 5.49 × 10−16
rs35940453 1.00 TLR4 Whole Blood C = 0.874 T = 0.126 −0.19938 5.49 × 10−16
rs7857333 1.00 TLR4 Whole Blood G = 0.874 A = 0.126 −0.19938 5.49 × 10−16
rs13299033 1.00 TLR4 Whole Blood A = 0.874 T = 0.126 −0.19938 5.49 × 10−16
rs35199804 1.00 TLR4 Whole Blood G = 0.874 T = 0.126 −0.19938 5.49 × 10−16
BMI-1 rs55654527 A - 0.34
rs957512 0.98 TLR4 Whole Blood T = 0.621 C = 0.379 0.105626 4.81 × 10−11
rs12001083 0.98 TLR4 Whole Blood C = 0.621 T = 0.379 0.105061 6.01 × 10−11
rs10759926 1.00 TLR4 Whole Blood T = 0.616 C = 0.384 0.097862 1.05 × 10−09
rs10116193 1.00 TLR4 Whole Blood A = 0.616 G = 0.384 0.097751 1.09 × 10−09
rs10983720 1.00 TLR4 Whole Blood A = 0.616 T = 0.384 0.097751 1.09 × 10−09
WHRadjBMI-1 rs13283416 - G 0.43 rs6478243 0.81 ASTN2 Adipose - Subcutaneous T = 0.621 C = 0.379 −0.17614 1.72 × 10−06
Neuroticim-1 rs579017 + T 0.06 rs579017 1.00 TLR4 Whole Blood T = 0.045 C = 0.955 0.205844 2.88 × 10−11
Mood-2 rs79825568 - A 0.48
rs928052 1.00 TLR4 Artery - Tibial G = 0.49 A = 0.51 −0.15591 4.98 × 10−8
rs13294726 1.00 TLR4 Artery - Tibial T = 0.49 C = 0.51 −0.15483 5.00 × 10−8
rs12236328 1.00 TLR4 Artery - Tibial A = 0.49 G = 0.51 −0.15608 5.68 × 10−8
rs1887905 1.00 TLR4 Artery - Tibial C = 0.49 G = 0.51 −0.15446 8.30 × 10−8
rs13293271 1.00 TLR4 Artery - Tibial A = 0.49 G = 0.51 −0.15418 8.40 × 10−8
rs928052 1.00 TLR4 Whole Blood G = 0.49 A = 0.51 −0.16194 8.12 × 10−25
rs13293271 1.00 TLR4 Whole Blood A = 0.49 G = 0.51 −0.16151 4.00 × 10−24
rs1887905 1.00 TLR4 Whole Blood C = 0.49 G = 0.51 −0.16208 4.50 × 10−24
rs913615 1.00 TLR4 Whole Blood C = 0.49 A = 0.51 −0.16069 8.92 × 10−24
rs4481681 1.00 TLR4 Whole Blood A = 0.49 G = 0.51 −0.16069 8.92 × 10−24
rs12236328 1.00 TLR4 Nerve - Tibial A = 0.49 G = 0.51 −0.17896 9.92 × 10−6
rs13293271 1.00 TLR4 Nerve - Tibial A = 0.49 G = 0.51 −0.1801 8.64 × 10−6
rs13294726 1.00 TLR4 Nerve - Tibial T = 0.49 C = 0.51 −0.18186 6.19 × 10−6
rs928052 1.00 TLR4 Nerve - Tibial G = 0.49 A = 0.51 −0.18426 4.40 × 10−6
Anhedonia-1 rs144850429 + T 0.01 rs144850429 1.00 ASTN2 Nerve - Tibial C = 0.99 T = 0.01 −0.62966 1.81 × 10−6
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The secondary signal for DBP influences TLR4 in whole blood, with the DBP-increasing
allele (rs34432054) associated with reduced levels of TLR4. Likewise, the primary signal
for BMI influences TLR4 in whole blood, with the BMI-decreasing allele (rs55654527) being
associated with increased levels of TLR4. The primary signal for neuroticism (rs579017) also
influences TLR4 in whole blood, with the neuroticism-increasing allele being associated
with increased levels of TLR4. Assessment of all SNPs with significant effects on at least
one trait for predicted effects on the genes or proteins demonstrated no moderate or severe
consequences.
4. Discussion
This candidate gene study sought to determine whether the ASTN2 locus might
contribute to shared mechanisms underlying CMD and SMI. We identified associations
between genetic variation in ASTN2 and cardiometabolic traits (specifically SBP, DBP, BMI,
WHRadjBMI) as well as traits of relevance to SMI (specifically neuroticism, mood instability
and anhedonia). We demonstrated that there is consistency in effects between CMD traits
and between SMI traits, but that the relationship between CMD and SMI traits is complex
and inconsistent within the locus.
ASTN2 is found on chromosome 9 and encodes a transmembrane protein expressed
primarily in the brain (Figure 10), largely in the cerebellum [19], therefore it is possible that
SNPs in this locus might act through ASTN2 to influence psychological traits. However,
it should be noted that the complex cognitive abilities which involve the cerebellum
are not necessarily features of the psychiatric traits we have assessed. The protein is
known to form a complex with surface membrane protein, ASTN1, and is thought to aid
neuronal migration through this interaction [43]. During later stages of development, it
is believed that ASTN2 is involved in expression [44] and translocation of a variety of
membrane receptors, thereby regulating synaptic functions [19]. Functional analysis has
demonstrated reduced electrophysical properties and aberrant connectivity in ASTN2
knockout neurons [45]. Thus it is plausible that the reduced ASTN2 levels being associated
with the same allele as increases risk of anhedonia suggests a lack synaptic signalling in
nerve tissue as a component of anhedonia biology. The fact that multiple signals in the
ASTN2 locus were associated (with consistent effects) with neuroticism, anhedonia, and
mood instability might suggest common mechanisms underlying these traits. Indeed,
our results agree with numerous studies demonstrating the association between mood
instability and neuroticism, which is reassuring, given that mood instability has been
described as a “distinctive feature of neuroticism” [46]. Prior studies have implicated this
locus in determining psychiatric traits [44,45,47,48] which overlap to varying degrees with
these intermediate traits, providing additional weight to the hypothesis that alterations in
synaptic signalling could underpin many psychological and psychiatric phenotypes.
The reduced levels of ASTN2 being associated with the same allele as reduced central
fat accumulation (WHRadjBMI) in adipose tissue is less easy to interpret. The ASTN2
locus has been associated with triglyceride levels [42] and there is clear crosstalk between
the central nervous system and metabolic regulation [49], but the exact role of ASTN2
requires elucidation. Studies of ASTN2 function have focused on neurodevelopmental
rather than anthropometric phenotypes [19,44,45] and no murine astn2 knockout models
have been developed. Mice lacking a brinp1, a member of the same protein family as
astn2, which is located nearby astn2 and has potentially overlapping functions has been
investigated [48]. These mice demonstrate reduced postnatal viability and reduced post-
natal weight gain [48]. Therefore, ASTN2 being the gene through which the WHRadjBMI
locus acts is reasonable but requires further investigation.
The lack of genotype-specific ASTN2 expression effects for neuroticism, mood instabil-
ity, blood pressure and BMI might imply that this is not the functional gene. However, as
maturation of the ASTN2 protein requires cleavage of a signal peptide in the endoplasmic
reticulum [50], with protein products remaining linked by a disulphide bond [51], genetic
variation in the signal peptide, the cleavage site and/or the cysteine residues in the di-
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sulphide bond would have severe functional effects not visible through mRNA analysis. It
also cannot be ruled out that the loci for mood instability, neuroticism, blood pressure and
BMI might be acting through other genes in the region, which is supported by their effects
on mRNA expression of TRIM32 and TLR4 (Table 4).
It is much harder to draw conclusions on the connection between cardiometabolic and
psychiatric health in this locus. Most of our data do not seem to support shared mechanistic
contribution to both psychiatric and cardiovascular health. Except for BMI, none of the
cardiometabolic lead SNPs are also significant in the psychiatric traits, and conditional
analyses as well as the LD structure do not suggest coinheritance of psychiatric and car-
diometabolic traits. However, the BMI association could have a behavioural explanation,
whereby ASTN2 influences food preferences as well as mood-related traits, and the food
preferences have subsequent effects on BMI: An experimental study in mice has demon-
strated that a high fat diet (which causes fat accumulation) can prompt an anhedonia-like
phenotype in a manner dependent upon gut microbiota and leptin signalling [52]. There
are caveats that should be considered when extrapolating murine studies to real-world
human populations. Whilst mice (nocturnal) can be given controlled diets (high fat or nor-
mal) and the effect of antibiotics (as a blunt way to change the gut microbiota), behaviour
of real-world humans (predominantly diurnal) is more complex, with food preferences,
healthcare seeking, medication adherence, physical activity patterns and mood-altering
substance use all being interrelated. So whilst this explanation is intriguing, it should be
considered with these caveats in mind. Given that the ASTN2 locus appears to be divided,
with one part having consistent direction of effects on CMD and SMI and the other part
having opposite effects on CMD and SMI in white British ancestry individuals, further
investigation of this locus is warranted
This work was based on the UK Biobank cohort, which is one of the largest studies
to date with genetic data as well as a wide range of cardiometabolic, psychological and
psychiatric phenotyping. Limitations of the cohort include its bias towards healthier
and wealthier individuals [53]. Psychiatric conditions, in particular, are rarer amongst
individuals who participated compared to the general population [53]. A cohort with
a higher prevalence of cardiometabolic and psychiatric conditions may have allowed
identification of further SNPs in the locus which could have been overlooked in this cohort.
Similarly, we analysed only individuals with White British ancestry, in order to minimise
genetic heterogeneity. Unfortunately, this means results are only generalisable to White
British ancestry individuals.
Future work is required to fully understand the role of the ASTN2 locus in mental and
physical health. Expanding this study to include high psychiatric and/or cardiometabolic
risk and/or prevalence populations would be of value, as would extending the study to
additional ancestry groups with different LD patterns. In particular, haplotype analyses
in a diverse ancestry individuals could elucidate the impact of the consistent/divergent
parts of the locus. Additional work in experimental models to better define the role of
ASTN2 and effects of reduced levels, particularly in neuronal and adipose tissue would be
of interest.
5. Conclusions
In summary, this study does not offer any strong evidence for shared genetic mecha-
nisms between cardiometabolic and psychiatric traits in the ASTN2 locus. However, we
do provide evidence for SNPs in this locus acting through ASTN2 to influence central fat
accumulation as well as risk of anhedonia. Whilst we cannot exclude the possibility of a
behavioural explanation (as proposed by [52]), the available evidence from experimental
studies is more supportive of pleiotropic effects on mental and physical health traits.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/genes12081194/s1, Supplementary Table S1: All significant SNPs for each trait in sex-
combined analysis.
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